Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
BCRX closed down 4.28 percent on Tuesday, June 27, 2017, on 42 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
Trend Table & Recent Alerts
|See historical BCRX trend table...|
|Date||Alert Name||Type||% Chg|
|Jun 27||Fell Below 50 DMA||Bearish||0.00%|
|Jun 27||Downside 200 DMA Break||Bearish||0.00%|
|Jun 27||New Uptrend||Bullish||0.00%|
|Jun 26||200 DMA Support||Bullish||-4.28%|
|Jun 26||Stochastic Reached Overbought||Other||-4.28%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more BCRX news...
|52 Week High||9.25|
|52 Week Low||2.8|
|200-Day Moving Average||5.9688|
|50-Day Moving Average||5.8578|
|20-Day Moving Average||5.63|
|10-Day Moving Average||5.868|
|Average True Range||0.3911|
|Chandelier Exit (Long, 3 ATRs)||5.4967|
|Chandelier Exit (Short, 3 ATRs)||6.2233|
|Upper Bollinger Band||6.2083|
|Lower Bollinger Band||5.0517|
|Percent B (%b)||0.66|
|MACD Signal Line||-0.0335|